Rechallenge of immune checkpoint inhibitors in advanced non-small cell lung cancer

被引：2

作者：

Lin, Gen ^{[1
]}

Wang, Zhijie ^{[2
]}

Chu, Qian ^{[3
]}

Hu, Yi ^{[4
]}

Huang, Dingzhi ^{[5
]}

Wang, Jun ^{[6
]}

Yang, Fan ^{[7
]}

Zhong, Wenzhao ^{[8
]}

Zhou, Chengzhi ^{[9
]}

Zhu, Bo ^{[10
]}

Ai, Xinghao ^{[11
]}

Cao, Baoshan ^{[12
]}

Cao, Yabing ^{[13
]}

Chen, Mingqiu ^{[14
]}

Chen, Xiaohui ^{[15
]}

Chu, Tianqing ^{[16
]}

Duan, Jianchun ^{[2
]}

Fan, Yun ^{[17
]}

Fang, Yong ^{[18
]}

Feng, Shuitu ^{[19
]}

Feng, Weineng ^{[20
]}

Guo, Hui ^{[21
]}

Han, Chengbo ^{[22
]}

He, Yong ^{[23
]}

Hong, Shaodong ^{[24
]}

Hu, Jie ^{[25
]}

Huang, Meijuan ^{[26
]}

Huang, Yan ^{[24
]}

Jiang, Da ^{[27
]}

Jiang, Kan ^{[1
]}

Jiang, Richeng ^{[5
]}

Jin, Bo ^{[28
]}

Jin, Shi ^{[29
]}

Li, Jisheng ^{[30
]}

Li, Min ^{[31
]}

Li, Ziming ^{[11
]}

Li, Chao ^{[32
]}

Lin, Jie ^{[33
]}

Liu, Anwen ^{[34
]}

Liu, Si-Yang Maggie ^{[35
]}

Yutao, Liu ^{[2
]}

Liu, Zhefeng ^{[4
]}

Liu, Zhe ^{[36
]}

Liu, Zhenhua ^{[37
]}

Liu, Zhentian ^{[38
]}

Liu, Zhigang ^{[39
]}

Lu, Yuping ^{[40
]}

Lv, Tangfeng ^{[41
]}

Ma, Zhiyong ^{[42
]}

Miao, Qian ^{[1
]}

机构：

[1] Fujian Med Univ, Fujian Canc Hosp, Clin Oncol Sch, Dept Thorac Oncol, Fuzhou, Peoples R China

[2] Chinese Acad Med Sci & Peking Union Med Coll, Natl Clin Res Ctr Canc, Canc Hosp, Dept Med Oncol,Natl Canc Ctr, Beijing, Peoples R China

[3] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Oncol, Wuhan, Peoples R China

[4] Chinese Peoples Liberat Army Gen Hosp, Dept Oncol, Beijing, Peoples R China

[5] Tianjin Med Univ Canc Inst & Hosp, Dept Biotherapy, Tianjin, Peoples R China

[6] Shandong First Med Univ, Shandong Prov Qianfoshan Hosp, Dept Radiol, Affiliated Hosp 1, Jinan, Peoples R China

[7] Peking Univ Peoples Hosp, Dept Thorac Surg, Beijing, Peoples R China

[8] Guangdong Prov Peoples Hosp, Guangdong Acad Med Sci, Guangdong Lung Canc Inst, Guangzhou, Peoples R China

[9] First Affiliated Hosp Guangzhou Med Univ, Guangzhou Inst Resp Hlth, Natl Clin Res Ctr Resp Dis, Natl Ctr Resp Med,State Key Lab Resp Dis,Dept Cri, Guangzhou, Peoples R China

[10] Army Med Univ, Xinqiao Hosp, Inst Canc, Chongqing, Peoples R China

[11] Shanghai Jiao Tong Univ, Sch Med, Shanghai Chest Hosp, Shanghai Lung Canc Ctr, Shanghai, Peoples R China

[12] Peking Univ Third Hosp, Dept Med Oncol & Radiat Sickness, Beijing, Peoples R China

[13] Kiang Wu Hosp, Dept Oncol, Macau, Peoples R China

[14] Fujian Med Univ, Clin Oncol Sch, Fujian Canc Hosp, Dept Radiat Oncol, Fuzhou, Peoples R China

[15] Fujian Med Univ, Fujian Canc Hosp, Dept Thorac Surg, Clin Oncol Sch, Fuzhou, Peoples R China

[16] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Resp Dept, Sch Med, Shanghai 200030, Peoples R China

[17] Zhejiang Canc Hosp, Dept Med Oncol, Hangzhou, Zhejiang, Peoples R China

[18] Zhejiang Univ, Sir Run Run Shaw Hosp, Sch Med, Dept Med Oncol, Hangzhou, Peoples R China

[19] Fudan Univ, Dept Radiat Oncol, Xiamen branch, Shanghai Canc Ctr, Xiamen, Peoples R China

[20] First Peoples Hosp Foshan, Dept Radiat Oncol, Foshan, Peoples R China

[21] First Affiliated Hosp Xian Jiaotong Univ, Dept Med Oncol, Xian 710061, Peoples R China

[22] Shengjing Hosp China Med Univ, Dept Oncol, Shenyang, Peoples R China

[23] Army Med Univ, Xinqiao Hosp, Dept Resp Med, Chongqing, Peoples R China

[24] Sun Yat sen Univ Canc Ctr, State Key Lab Oncol Southern China, Guangzhou, Peoples R China

[25] Fudan Univ, Shanghai Zhongshan Hosp, Canc Ctr, Shanghai, Peoples R China

[26] Sichuan Univ, West China Hosp, Canc Ctr, Div Thorac Tumor Multimodal Treatment, Chengdu, Peoples R China

[27] Fourth Affiliated Hosp Hebei Med Univ, Dept Orthoped, Shijiazhuang, Herts, Peoples R China

[28] First Hosp China Med Univ, Dept Med Oncol, Shenyang, Peoples R China

[29] Chinese Acad Med Sci & Perking Union Med Coll, Natl Canc Ctr, Natl Clin Res Ctr Canc, Canc Hosp, Shenzhen 518116, Peoples R China

[30] Qilu Hosp Shandong Univ, Dept Med Oncol, Jinan, Peoples R China

[31] Cent South Univ, Xiangya Hosp, Dept Resp Med, Changsha, Peoples R China

[32] Fujian Med Univ, Fujian Canc Hosp, Dept Pathol, Clin Oncol Sch, Fuzhou, Peoples R China

[33] Second Affiliated Hosp Kunming Med Univ, Dept Hematol, Kunming, Peoples R China

[34] Second Affiliated Hosp Nanchang Univ, Dept Vasc Surg, Nanchang, Peoples R China

[35] Jinan Univ, Affiliated Hosp 1, Dept Hematol, Guangzhou, Peoples R China

[36] Capital Med Univ, Beijing Chest Hosp, Dept Med Oncol, Beijing, Peoples R China

[37] Fujian Med Univ, Fujian Prov Hosp, Shengli Clin Med Coll, Dept Oncol, Fuzhou, Peoples R China

[38] Jiangxi Canc Hosp, Dept Thorac Oncol, Nanchang, Peoples R China

[39] Southern Med Univ, Affiliated Dongguan Hosp, Ctr Canc, Dongguan, Guangdong, Peoples R China

[40] Fujian Med Univ, Fujian Canc Hosp, Dept Abdominal Oncol, Clin Oncol Sch, Fuzhou, Peoples R China

[41] Nanjing Univ, Jinling Hosp, Dept Resp Med, Sch Med, Nanjing, Peoples R China

[42] Zhengzhou Univ, Henan Canc Hosp, Affiliated Canc Hosp, Dept Resp Med, Zhengzhou, Peoples R China

[43] Wuhan Univ, Renmin Hosp, Wuhan, Peoples R China

[44] Cent South Univ, Dept Thorac Med Oncol, Hunan Canc Hosp, Affiliated Canc Hosp,Xiangya Sch Med, Changsha, Peoples R China

[45] Tianjin Med Univ, Canc Inst & Hosp, Dept Biotherapy, Tianjin, Peoples R China

[46] Zhejiang Univ, Affiliated Hosp 1, Dept Nucl Med, Hangzhou, Zhejiang, Peoples R China

[47] Army Med Univ, Daping Hosp, Dept Radiat Oncol, Chongqing, Peoples R China

[48] Southern Med Univ, Nanfang Hosp, Dept Oncol, Guangzhou, Peoples R China

[49] Nanjing Med Univ, Affiliated Canc Hosp, Jiangsu Inst Canc Res, Dept Med Oncol,Jiangsu Canc Hosp, Nanjing, Peoples R China

[50] Zhejiang Canc Hosp, Dept Clin Trial, Hangzhou, Peoples R China

来源：

THORACIC CANCER | 2024年 / 15卷 / 05期

关键词：

ICI; NSCLC; re-challenge; NIVOLUMAB; PEMBROLIZUMAB; EFFICACY; PLACEBO; NSCLC;

D O I：

10.1111/1759-7714.15209

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Immune checkpoint inhibitor (ICI) rechallenge in non-small cell lung cancer (NSCLC) is a promising therapeutic strategy. The situation for ICI rechallenge can be divided into three categories: adverse events (AEs); resistance to ICIs, and rechallenge becomes compulsive because of tumor relapse while the patients had completed a 2 year course of immunotherapy. However, these categories are still controversial and should be explored further. Through voting at the 6th Straits Summit Forum on Lung Cancer, in this study we summarize the consensus of 147 experts in ICI rechallenges. A total of 97.74% experts agreed to rechallenge; 48.87% experts rechallenge with the original drug, and the others rechallenge with a different drug; 40.3% agreed to rechallenge directly after progression; 88.06% experts agreed to ICI rechallenge with a combination regimen; and factors such as previous performance status score, PD-1 expression, and age should also be considered. Understanding the the clinical studies in ICI rechallenge could bring us one step closer to understanding the consensus. In patients with advanced NSCLC who have suffered recurrent or distant metastasis after immunotherapy, the option of rechallenge with ICIs is a promising treatment option.

引用

页码：419 / 426

页数：8

共 50 条

[1] Efficacy and predictors of rechallenge with immune checkpoint inhibitors in non-small cell lung cancer
Takahara, Yutaka
Tanaka, Takuya
Ishige, Yoko
Shionoya, Ikuyo
Yamamura, Kouichi
Sakuma, Takashi
Nishiki, Kazuaki
Nakase, Keisuke
Nojiri, Masafumi
Kato, Ryo
Shinomiya, Shohei
Fujimoto, Yuki
Oikawa, Taku
Mizuno, Shiro
[J]. THORACIC CANCER, 2022, 13 (04) : 624 - 630
[2] Immune checkpoint inhibitors in advanced non-small cell lung cancer
Fabre, Elizabeth
Pecuchet, Nicola
Cadranel, Jacques
[J]. BULLETIN DU CANCER, 2016, 103 : S138 - S143
[3] Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer
Assi, Hazem I.
Kamphorst, Alice O.
Moukalled, Nour M.
Ramalingam, Suresh S.
[J]. CANCER, 2018, 124 (02) : 248 - 261
[4] The role of immune checkpoint inhibitors in advanced non-small cell lung cancer
Pistamaltzian, Nikolaos F.
Georgoulias, Vassilis
Kotsakis, Athanasios
[J]. EXPERT REVIEW OF RESPIRATORY MEDICINE, 2019, 13 (05) : 435 - 447
[5] Immune checkpoint inhibitors rechallenge in non-small cell lung cancer: Current evidence and future directions
Gang, Xiaoyu
Yan, Jinshan
Li, Xin
Shi, Sha
Xu, Lu
Liu, Ruotong
Cai, Lutong
Li, Heming
Zhao, Mingfang
[J]. CANCER LETTERS, 2024, 604
[6] Immune checkpoint inhibitors in non-small cell lung cancer
Eberhardt, Wilfried Ernst Erich
[J]. ONKOLOGE, 2017, 23 (10): : 838 - 844
[7] Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer
Herzberg, Benjamin
Campo, Meghan J.
Gainor, Justin F.
[J]. ONCOLOGIST, 2017, 22 (01): : 81 - 88
[8] The effect and safety of immune checkpoint inhibitor rechallenge in non-small cell lung cancer
Watanabe, Hiromi
Kubo, Toshio
Ninomiya, Kiichiro
Kudo, Kenichiro
Minami, Daisuke
Murakami, Etsuko
Ochi, Nobuaki
Ninomiya, Takashi
Harada, Daijiro
Yasugi, Masayuki
Ichihara, Eiki
Ohashi, Kadoaki
Fujiwara, Keiichi
Hotta, Katsuyuki
Tabata, Masahiro
Maeda, Yoshinobu
Kiura, Katsuyuki
[J]. JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2019, 49 (08) : 762 - 765
[9] Immune checkpoint inhibitor rechallenge in advanced or metastatic non-small cell lung cancer: a retrospective cohort study
Xu, Ziyi
Hao, Xuezhi
Yang, Ke
Wang, Qi
Wang, Jing
Lin, Lin
Teng, Fei
Li, Junling
Xing, Puyuan
[J]. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2022, 148 (11) : 3081 - 3089
[10] Safety and efficacy of immune checkpoint inhibitor rechallenge in advanced non-small cell lung cancer: a retrospective study
Feng, Jia
Chen, Xinyi
Wei, Jiayan
Weng, Yiming
Wang, Jingsong
Wang, Tong
Song, Qibin
Min, Peng
[J]. SCIENTIFIC REPORTS, 2024, 14 (01)

← 1 2 3 4 5 →